Dizhe Pharmaceutical announced that the two latest research results on EGFR 20 exon insertion mutant advanced non-small cell lung cancer (NSCLC), a Class I novel lung cancer target drug independently developed by the company, will be announced at the 2024 ASCO annual meeting. Among them, the “Wukong Part 1B” research data will be published for the first time in the form of an oral report. Preliminary analysis results show that Schwarzer 2/laterline treatment of EGFR exon20ins mutant nsCLC showed positive anti-tumor efficacy and was safe. Another study showed that patients with both positive and negative EGFR exon20ins mutations were observed after receiving Schwarzer treatment with baseline plasma ctDNA. The objective response rate (ORR) was 68.0% and 45.8%, respectively, and the median progression-free survival (MPFs) was 7.4 months and 5.5 months. Furthermore, the resistance mechanism of Schwarzell shows EGFR-dependent and independent pathways, and golisitinib in combination with chemotherapy may be a potential solution.